Omnihealth Practice

Hybrid GLP-1 RA and digital coaching programme delivers sustained weight loss and metabolic benefits

Hybrid obesity care combining glucagon-like peptide-1 receptor agonists (GLP-1 RAs) with app-based lifestyle coaching delivered sustained weight loss and cardiometabolic improvements over 18 months in a real-world study in Singapore. Higher digital engagement further enhanced outcomes, supporting integrated hybrid models as a scalable approach to long-term obesity management.

DIABETES & ENDOCRINOLOGY

22 Jun 2026

MASLD drives persistent HCC risk despite HCV cure: Insights from a Japanese multicenter cohort study

A large multicenter cohort study revealed that metabolic dysfunction-associated steatotic liver disease (MASLD) remains a significant factor in the risk of hepatocellular carcinoma (HCC) even after chronic hepatitis C (HCV) has been eradicated with direct-acting antivirals (DAAs). These findings underscore the importance of post-cure risk stratification, long-term surveillance, and management of metabolic dysfunction to mitigate the residual burden of HCC.

GASTROENTEROLOGY & HEPATOLOGY

30 Jan 2026

Parity and breastfeeding establish durable CD8⁺ T cell-mediated protection in TNBC

Triple-negative breast cancer (TNBC) is characterized by higher immune infiltration compared with other breast cancer subtypes. Parity and breastfeeding are established protective factors for breast cancer, particularly TNBC, reducing risk by approximately 7% per full-term birth and an additional 4.3% for every 12 months of breastfeeding.

ONCOLOGY OBSTETRICS & GYNECOLOGY

16 Dec 2025

Lighting the path: How sentinel nodes guide EC care

In a recent expert discussion with Professor Nirmala Kampan, she shared her perspectives on the evolving role of this technique, from evidence-based outcomes to future innovation and directions in patient-centered care in EC.

OBSTETRICS & GYNECOLOGY ONCOLOGY

26 Nov 2025

Professor Dr. Nirmala Kampan

Consultant Obstetrician & Gynecologist,
Hospital Canselor Tuanku Muhriz UKM (HCTM-UKM),
Head of the Gyne-Oncology and Minimally Invasive Surgery Units,
Faculty of Medicine, Universiti Kebangsaan Malaysia (UKM),
Kuala Lumpur, Malaysia

Guide to OSA in Hong Kong: Enhancing primary care response

In an interview with Dr. To, Wing-Hei Zion, he discussed the critical, yet often overlooked, issue of OSA within the local population. He highlighted that OSA is far more than a simple snoring problem; it is a systemic disease linked to a cascade of serious comorbidities, including hypertension, stroke, and diabetes. He provided a comprehensive overview for family medicine and GPs, covering practical screening methods, navigating local diagnostic pathways, and the latest patient-centered management, underscoring their vital role in improving long-term health outcomes by addressing this hidden epidemic.

20 Oct 2025

Dr. To, Wing-Hei Zion

Clinical Assistant Professor (Honorary),
Department of Otorhinolaryngology,
Head and Neck Surgery,
The Chinese University of Hong Kong

AAN 2026

April 18-22, 2026 | Chicago, United States

Donanemab delivers durable clinical and biomarker benefits over 3 years in early AD

TRAILBLAZER-ALZ 2 long-term extension analyses showed sustained clinical and biomarker effects of donanemab over 3 years in early Alzheimer’s disease (AD). Most participants achieved amyloid plaque clearance, with clinical benefits persisting after treatment discontinuation. No new safety signals emerged, confirming the long-term durability of donanemab.

NEUROLOGY

12 Jun 2026

rWGS demonstrates meaningful diagnostic utility in hospitalized adults with unexplained neurological manifestations

A retrospective study showed that rapid whole genome sequencing (rWGS) diagnosed nearly one-quarter of hospitalized adults with unexplained neurological manifestations. The approach identified monogenic disorders, successfully guiding targeted patient management. Diagnostic yield was highest in individuals presenting with multisystem involvement, family history, psychiatric symptoms, or unexplained ataxia.

NEUROLOGY

08 Jun 2026

ASH 2025

December 6-9 , 2025 | Orlando, United States

Ponatinib + blinatumomab vs. imatinib + chemotherapy in newly diagnosed adult Ph+ ALL: First results from the GIMEMA ALL2820 trial

The GIMEMA ALL2820 trial evaluated a chemo-free strategy with ponatinib + blinatumomab vs. imatinib + chemotherapy in adults with newly diagnosed Ph+ ALL. The initial results show that the experimental arm achieved higher complete hematologic response and minimal residual disease negativity, along with improved event-free survival and OS, and a manageable safety profile.

HEMATOLOGY

30 Jan 2026

Efanesoctocog alfa offers sustained prophylaxis in severe hemophilia A: Interim analysis of the XTEND-ed LTE study

STUDY DESIGN Efanesoctocog alfa is a first-in-class high-sustained factor VIII (FVIII) replacement therapy designed to decouple recombinant FVIII from endogenous von Willebrand factor, providing prolonged FVIII activity.1 The phase 3 XTEND-1 study in adults/adolescents and XTEND-Kids study in child

HEMATOLOGY

27 Feb 2026

Hybrid GLP-1 RA and digital coaching programme delivers sustained weight loss and metabolic benefits

DIABETES & ENDOCRINOLOGY

22 Jun 2026

Enhancing early lung cancer detection: Insights from HKU's lung nodule surveillance programme

Lung cancer remains one of the leading causes of cancer-related deaths in Hong Kong, with survival strongly linked to early-stage diagnosis. Despite advances in imaging, many lung cancers go undetected or are diagnosed late, limiting treatment options and outcomes.

ONCOLOGY

23 Nov 2025

CU Medicine and global experts develop Chinese-specific genetic risk score for T1D diagnosis

Accurate diagnosis of type 1 diabetes remains a major clinical challenge, with up to 40% of adults initially misclassified as having type 2 diabetes, leading to delayed insulin initiation and increased risk of complications. Most existing genetic risk scores were derived from European populations, with limited applicability in Asian populations due to differences in genomic architecture. This highlights the need for ancestry-specific tools. A study led by a joint research team from The Chinese University of Hong Kong (CUHK), the University of Exeter in the United Kingdom, and the Second Xiangya Hospital of Central South University in China developed and validated a Chinese-specific T1D genetic risk score that improves differentiation between T1D and T2D compared to European-derived models.

DIABETES & ENDOCRINOLOGY

29 Oct 2025

SC daratumumab approved in the EU as first treatment for high-risk SMM

Smoldering multiple myeloma (SMM) is an asymptomatic precursor of multiple myeloma, with high-risk patients facing a substantial likelihood of progression to symptomatic disease. Until now, there have been no approved treatment options for this patient population, and standard care has been limited to close monitoring. The recent European Commission (EC) approval of subcutaneous daratumumab, based on phase 3 AQUILA trial results, introduces the first licensed treatment for high-risk SMM and provides a new opportunity to delay or prevent progression to symptomatic disease.

HEMATOLOGY

16 Oct 2025

Momelotinib: Explore MOMGEMFIN as largest real world data

HEMATOLOGY

11 Mar 2026

Raising the bar in AD care: Delivering deep and durable responses with lebrikizumab

Highlights Atopic dermatitis (AD) is driven by a cycle of barrier dysfunction and type 2 inflammation, with interleukin (IL)-13 playing a central role While traditional corticosteroids can control flares, they do not fully address the underlying immune-barrier interplay, l

DERMATOLOGY

09 Oct 2025

Professor Florian Lordick

Director, Comprehensive Cancer Center Central Germany (CCCG)
Director, Department of Medicine, University of Leipzig,
Germany

Every update. In your inbox.

Get access to our exclusive articles.

Extending endocrine care beyond β-thalassemia major: International consensus guideline in children and adolescents

Thalassemia arises from mutations in the α- or β-globin genes, with 5%-10% of the global population carrying α-thalassemia mutations and at least 40,000 children born with β-thalassemia annually. The disease is most prevalent in the Mediterranean, Middle East, Indian subcontinent, China, and Southeast Asia.

HEMATOLOGY PEDIATRICS

07 Nov 2025

Professor Dr. Muhammad Yazid Jalaludin

Senior Consultant Pediatric Endocrinologist,
Department of Pediatrics,
Universiti Malaya Medical Centre,
Kuala Lumpur, Malaysia

Empirical PPI therapy and subtype-based treatment show similar efficacy in FD

Functional dyspepsia (FD) is a common gut-brain interaction disorder that primarily affects adults and imposes a significant economic burden.¹ Treatment guidelines vary, leading to inconsistencies in management approaches.¹ A randomized, single-blinded trial was conducted to evaluate the efficacy of subtype-specific treatment vs. empirical proton pump inhibitor (PPI) therapy in adults with FD.¹ Findings suggest that both treatment approaches significantly improved the overall symptoms and health-related quality of life (HRQoL), with no clear advantage of either, over another in FD management.¹

GASTROENTEROLOGY & HEPATOLOGY

12 Jun 2025

Dr. Chuah, Kee-Huat

Associate Professor
Consultant Gastroenterologist & Hepatologist
Faculty of Medicine, University of Malaya,
Kuala Lumpur, Malaysia

Dual immunotherapy combination in pre-treated HCC: A case study in achieving 10-year remission

In an interview with Professor Yau, Chung-Cheung Thomas, he shared a case of 10-year survival in a patient with metastatic aHCC in the second-line setting managed with dual immune checkpoint inhibitors nivolumab + ipilimumab. Dr. Wong, Sum-Lung Jeffrey also provided insights into data from the CheckMate 040 trial and its Asian subgroup analysis, highlighting not only the efficacy and durability of the dual immune checkpoint inhibitors but also their manageable safety profile. The combination of nivolumab + ipilimumab marks a paradigm shift in HCC treatment, offering hope for long-term survival in a disease once considered universally fatal.

ONCOLOGY GASTROENTEROLOGY & HEPATOLOGY

26 Jan 2026

Professor Yau, Chung-Cheung Thomas

Clinical Associate Professor,
Centre of Cancer Medicine/
Department of Medicine
School of Clinical Medicine,
LKS Faculty of Medicine,
The University of Hong Kong

Dr. Wong, Sum-Lung Jeffrey

Fellow in Medical Oncology

Brexpiprazole augmentation achieving remission in MDD with anxiety features during long-term venlafaxine maintenance: A case report

Major depressive disorder (MDD) remains a challenging psychiatric condition, with nearly half of patients failing to achieve an adequate response to initial antidepressant therapy (ADT).1 Traditional augmentation strategies, including second-generation antipsychotics, may offer symptomatic relief bu

PSYCHIATRY

05 Jan 2026

Cabozantinib combinations leading the way in RCC: Transformative therapies backed by real-world success

ONCOLOGY

20 May 2026

Dr. Su, Po-Jung

Attending Physician in Medical Oncology, Division of Oncology,
Department of Internal Medicine Chang Gung Memorial Hospital, Linkou, Taiwan

Optimizing bipolar disorder treatment with antipsychotics and long-acting injectables

PSYCHIATRY

25 Mar 2026

Dr. Lin, Shih-Ku

Attend Psychiatrist,
Taipei Chang Gung Memorial Hospital,
Taiwan
Vice President, Asian College of
Neuropsychopharmacology (AsCNP)

Dr. Fang, Chun-Kai

Chief,
Hospice and Palliative Care Center,
MacKay Memorial Hospital,
Taiwan

Infographics

HEMATOLOGY

The TRACTION trial: Slashing transfusions in major non-cardiac surgery with TXA

28 Apr 2026

DERMATOLOGY

Better plate for clearer skin: Mediterranean diet reduces psoriasis burden

29 Jan 2026

HEMATOLOGY

Extending treatment with brentuximab vedotin to stage III classical Hodgkin lymphoma

23 Jan 2026

RHEUMATOLOGY

Decoding SSc-ILD in Hong Kong: Epidemiological Insights and Predictive Biomarkers

22 Sep 2025

OBSTETRICS & GYNECOLOGY ONCOLOGY DIABETES & ENDOCRINOLOGY CARDIOLOGY

Double jeopardy: Obesity + CVD linked to higher postmenopausal breast cancer risk

17 Sep 2025

NEUROLOGY

Dreams that steal time: Associating distressing dreams with early mortality

25 Jul 2025

IMMUNOLOGY & ALLERGY

CHOOSE THE RIGHT PROTECTION FOR YOU: A Guide to Subcutaneous (SC) or Intravenous (IV) Immunoglobulin (Ig)

25 Jul 2025

HEMATOLOGY ONCOLOGY

The Hidden Blueprint: CGAT Reveals Key Insights for Myelofibrosis Transplant

06 Apr 2025

DERMATOLOGY

Beneath The Surface Exploring Metabolic Syndrome in Chronic Spontaneous Urticaria

10 Feb 2025

OBSTETRICS & GYNECOLOGY PSYCHIATRY CARDIOLOGY

Heartfelt Connections: The Shadow of PND on Maternal CV Health

03 Dec 2024

OPHTHALMOLOGY NEPHROLOGY

Insight into CKD progression: Ophthalmalogical outcomes and eGFR in non-diabetic CKD

21 Jun 2024

CARDIOLOGY

CKD or No CKD: Knocking down CV risks with rosuvastatin

08 Jul 2024

NEUROLOGY

Longitudinal assessment of MCI and dementia in an essential tremor cohort

08 Jul 2024

HEMATOLOGY

From bridging to maintenance: A case of gilteritinib in RR FLT3 AML patients undergoing HSCT

09 May 2024

NEUROLOGY

Real-world effectiveness of fremanezumab in migraine prevention

08 Apr 2024

HEMATOLOGY CARDIOLOGY

Incidence of anemia with long-term low-dose aspirin

18 Mar 2024

Decoding the spectrum of tolerance in fish allergies

04 Jan 2024

DIABETES & ENDOCRINOLOGY CARDIOLOGY

Earlier and higher risk of CVD with a younger T2D diagnosis

04 Jan 2024

DIABETES & ENDOCRINOLOGY

U-shaped relationship between sleep duration and T2DM regardless of traditional lifestyle risk factors

17 Nov 2023

RESPIROLOGY

Brain Gliosis: A Potential Origin of Persistent Post-COVID-19 Depressive and Cognitive Symptoms

17 Nov 2023

DIABETES & ENDOCRINOLOGY NEUROLOGY

The nuanced link between prediabetes and dementia

23 Aug 2023

NEUROLOGY RHEUMATOLOGY

Connecting the dots between Parkinson’s disease and rheumatoid arthritis

12 Jul 2023

CARDIOLOGY PEDIATRICS

Cardio-oncology monitoring in pediatric populations - Delphi consensus recommendations from an Australian and New Zealand expert group

28 Apr 2023

RESPIROLOGY IMMUNOLOGY & ALLERGY

Targeting TSLP for severe asthma - Tezepelumab updates from the 2023 American Academy of Allergy Asthma & Immunology Annual Meeting

06 Apr 2023

HEMATOLOGY PEDIATRICS

A new way out for alpha thalassemia major - Give them a chance at life with In-utero transfusions

15 Mar 2023

RESPIROLOGY

Beware of overlapping phenotypes in severe asthma: The eosinophilia and IgE double whammy

27 Feb 2023

NEPHROLOGY

Stay on the path of treatment - Take on a high-K with ease
ASN abstract highlight on sodium zirconium cyclosilicate and hyperkalemia

23 Feb 2023

RESPIROLOGY

Real-world effectiveness of benralizumab around the globe

06 Dec 2022

RESPIROLOGY

Remission is within reach - Target the underlying drivers of inflammation with benralizumab

19 Sep 2022

ONCOLOGY RESPIROLOGY

PACIFIC-6: Durvalumab after CRT showed similar safety profile as the PACIFIC regimen with encouraging efficacy data in frailer and older patients with stage 3, unresectable NSCLC